A year after Novo Nordisk surrendered its pursuit of an approval in the U.S. for IcoSema as a treatment for Type 2 diabetes, the Danish company has scored a recommendation for the combination drug in ...
For the second time in six months, Europe’s Committee for Medicinal Products for Human Use (CHMP) has given a thumbs down to Apellis’ Syfovre for the treatment of patients with geographic atrophy (GA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results